Moolec Science (MLECW) Net Income towards Common Stockholders (2022 - 2025)
Moolec Science (MLECW) posted Net Income towards Common Stockholders of $153317.0 for Q4 2025, down 74.25% sequentially from $595351.0 in Q4 2024, and down 74.25% YoY from $595351.0 in Q4 2024.
Moolec Science (MLECW) Net Income towards Common Stockholders (2022 - 2025) Analysis & Trends
Moolec Science has reported Net Income towards Common Stockholders for 4 years, with the latest figure at $153317.0 in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 74.25% year-over-year to $153317.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $748668.0 (changed N/A YoY) and the FY2024 annual result came in at -$32.9 million, down 181.3% from the prior year.
- Net Income towards Common Stockholders eased to $153317.0 in Q4 2025 per MLECW's latest filing, from $595351.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $48.0 million in Q4 2022 and troughed at -$15.7 million in Q2 2023.
- A 4-year average of $3.1 million and a median of -$721426.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 69.28% in 2023, down 232.1% in 2023.
- Over 4 years, Net Income towards Common Stockholders stood at $48.0 million in 2022, then tumbled by 83.15% to $8.1 million in 2023, then sank by 92.63% to $595351.0 in 2024, then plunged by 74.25% to $153317.0 in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $153317.0, $595351.0, and -$2.0 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 153,317.00 |
| Dec 31, 2024 | 595,351.00 |
| Sep 30, 2024 | -1.97 Mn |
| Jun 30, 2024 | -5.45 Mn |
| Mar 31, 2024 | -1.15 Mn |
| Dec 31, 2023 | 8.08 Mn |
| Sep 30, 2023 | -1.81 Mn |
| Jun 30, 2023 | -15.67 Mn |
| Mar 31, 2023 | -358,578.00 |
| Dec 31, 2022 | 47.96 Mn |
| Sep 30, 2022 | -721,426.00 |
| Jun 30, 2022 | 11.86 Mn |
| Mar 31, 2022 | -1.17 Mn |